Phase IIPeptide
Compound 61453
Formula Pending
Molecular Mass
N/A
CAS Registry
AUTO-061453
Risk Class
MODERATE
Last Audit
Feb 16, 2108
Research Abstract
Peptide candidate engineered for oncology adjuvant initiatives with automated dossier coverage.
Compound 61453 is a peptide asset inside peptide innovation track initiatives, optimized for oncology adjuvant and inflammation control.
The dossier currently sits in phase ii with a moderate risk rating, meaning it is requires layered oversight with metabolic labs.
Supply records cite CAS AUTO-061453 with updates logged 2108-02-16.
Acquisition Protocol
Authorized research personnel may request deployment of this compound for laboratory analysis.
Primary Vectors
Oncology adjuvantInflammation control
Nomenclature
CX-61453Peptide Program 61453
Reference Material
- [1] Anubis Compound Registry • CAS AUTO-061453
- [2] Operations Pulse • Peptide innovation track
- [3] Risk Governance Ledger • MODERATE clearance for COMPOUND-61453